Introduction
Neoadjuvant chemotherapy is a standard of care for patients with inoperable or high risk operable breast cancer with the aim to reduce the extent of surgery. 1 In addition, information on response obtained at surgery is used not only to assess long-term prognosis of patients but also as a short-term endpoint to evaluate efficacy of established treatments in an individual patient or of innovative regimens within a clinical trial situation. Pathological complete response (pCR) is considered as a surrogate efficacy endpoint generally correlated with favorable long-term outcome. However, a recent meta-analysis proposed that pCR is linked with a better prognosis for patients with hormone-receptor-negative (triple-negative or HER2-positive) tumors but only for a minority of patients with hormone-receptor-positive tumors. 2 Another benefit of neoadjuvant chemotherapy was recently reported for the GeparTrio study: an interim-response-guided chemotherapy modification resulted in a better overall survival when compared to conventional fixed-schedule chemotherapy. 3 Participants of the GeparTrio study received two initial cycles of neoadjuvant chemotherapy and response was assessed thereafter clinically. Patients with an interim response were randomized to four or six further cycles of the same chemotherapy whereas patients without interim response were randomized to continue the same chemotherapy or to switch to another. No differences in pCR and sonographic response rates were observed between the randomized arms, respectively. 4, 5 However, follow up revealed that patients being treated with the response-guided treatments showed a better disease-free and overall survival (OS) than patients being treated conventionally. This survival gain was observed only in patients with hormone-receptor-positive tumors. 3 Our hypothesis for this study was built on the above observation: For patients with hormone-receptor-positive tumors pCR is an infrequent event not strongly correlated with prognosis. Therefore pCR cannot forecast a survival benefit. Other surrogate efficacy endpoints after or under neoadjuvant chemotherapy for patients with hormone-receptorpositive tumors are therefore needed. 6 Tumor proliferation is considered to have the potential for such a new surrogate marker. 7 If
Ki67, a nuclear protein in cycling cells indicating tumor proliferation, 8,9,10 is detected in a substantial fraction of tumor cells, patients are at high risk for relapse and death due to
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Author Manuscript Published OnlineFirst on June 27, 2013; DOI: 10.1158/1078-0432.CCR- breast cancer. 11, 12 High percentage of cells expressing Ki67 in the initial tumor biopsy was correlated with a higher rate of pCR after neoadjuvant chemotherapy 13, 14, 15, 16 and preliminary studies suggest that Ki67 levels measured after neoadjuvant chemotherapy are of prognostic value for survival. 17, 18, 19, 20 Patients and Methods
Objectives
The aim of this prospectively planned translational research project was to evaluate the prognostic and predictive impact of post-treatment Ki67 levels in surgical specimens from participants of the GeparTrio trial. We postulated that patients without a pCR to neoadjuvant chemotherapy are heterogeneous and can be subdivided by post-treatment Ki67 levels into subgroups with good or worse prognosis. We hypothesized that responseguided treatment increases the frequency of tumors with low post-treatment Ki67 levels compared to conventional treatment if they were hormone-receptor-positive, but not if they were hormone-receptor-negative.
Patients
Patients with untreated unilateral or bilateral primary breast cancer were enrolled between underwent surgery. Those with progression were excluded from randomization and treated at the investigator's discretion. Postoperative radiotherapy and endocrine treatment was given according to national guidelines.
Methods
The project was conducted according to the REporting of tumor MARKer Studies (REMARK) guideline 23 and to a prospectively written research, pathological evaluation, and statistical analysis plan. Ki67 was assessed blinded to the clinical data by immunohistochemistry on the Ventana Discovery autostainer (Ventana, Tucson, USA) using the antibody MIB-1 as pCR was defined as no residual invasive disease in any excised breast tissue irrespective of nodal involvement (ypT0/is ypN0/+). This is different to previous publications on this study 4, 5, 24 as these are the patients where measurement of Ki67 at the surgical specimen is per se not possible. Histological response was evaluated locally but the pathology reports were centrally reviewed.
Positive ER and/or PR status was defined as ≥10% positive stained cells or a Remmele intensity and positivity score ≥3. 25 HER2 status was assessed by immunohistochemistry (positive if 3+) or in-situ hybridization.
Research. withdrawing consent, or lost to follow-up were censored at the date of last contact.
Statistical analysis
All analyses were performed on an intent-to-treat basis in randomized patients with either available surgical tissue for Ki67 measurement or with a pCR (n=1151) (Figure 1 ). Differences between those study participants included and not included in this analysis are shown in supplemental Table 1 . Patients subgroups were compared using Kendals Tau-c test for correlation. Time to event outcome parameters were estimated using the Kaplan-Meier product-limit method and treatment groups were compared using the log-rank test. Cox proportional hazards models were used to calculate hazard ratios (HR); 95% confidence Additionally, 484 patients were included in the analysis that had a pCR at surgery so that assessment of Ki67 level was not possible. Of note, patients with pCR are over-represented as no surgical tissue collection was required. Of these 1151 patients, representing 56% of the initial trial population, 562 patients were treated by conventional 6 cycles TAC, 575 patients with response-guided eight cycles TAC or TAC-NX, and 14 patients were not randomized.
During a median follow up of 5.2 years 264 relapses and 158 deaths were observed.
For the 667 patients with available tumor tissue, post-treatment Ki67 was low (0% to 15%) in 488 patients, intermediate (15. 1% to 35%) in 77 patients, and high (>35%) in 102 patients ( Table 1) . Post-treatment Ki67 levels were higher in tumors with a diameter ≥40 mm, nodepositive disease, undifferentiated tumors, hormone-receptor-negative tumors, and tumors with high pre-treatment Ki67 levels than in tumors of the corresponding opposite groups.
Patients with high post-treatment Ki67 levels showed higher risk for disease relapse (p<.0001) and death (p<.0001) compared to patients with low or intermediate Ki67 levels Ki67 levels (Figure 2e-f) . Indeed, patients with a decrease from high pre-treatment levels to low post-treatment levels or pCR showed a more sustained low relapse rate after three years compared to those patients with low or intermediate levels right from the beginning. Multivariable Cox regression models examined the additional information deriving from Ki67 measurements at surgery ( Table 2) 
Ki67 levels were observed numerically more often after response-guided chemotherapy, in particular in patients with hormone-receptor-positive tumors and in patients after TAC-NX than after conventional chemotherapy ( Table 1) . Post-treatment Ki67 levels discriminated similarly patients with different prognosis after conventional (HR 1.68) as well as after response-guided (HR 1.64) chemotherapy (Figure 3) . STEPP analysis investigated differences in disease-free survival of conventional versus response-guided over all post-treatment Ki67 level subgroups (Supplemental Figure) . As shown previously no difference in outcome was observed between the two treatment groups with hormone-receptor-negative disease, which was also the case over all post-treatment Ki67 subgroups. However, patients with hormone-receptor-positive tumors showed the largest differences in mean disease-free survival between conventional and response-guided chemotherapy if post-treatment Ki67 levels were between 20% and 70% in the STEPP analysis.
Discussion
Centrally assessed nuclear Ki67 expression after neoadjuvant chemotherapy in a subset of 1151 primary breast cancer patients from a randomized neoadjuvant clinical trial revealed that post-treatment Ki67 adds independent prognostic information surmounting that of pCR regarding the outcome after surgery. However, it appeared that it can provide additional information over pCR particularly in patients with hormone-receptor-positive disease where the prognostic impact of pCR is limited. We could not demonstrate that response-guided systemic treatments led to reduced Ki67 levels at surgery which was the predefined hypothesis. Therefore this marker cannot improve pCR as a surrogate endpoint marker for neoadjuvant clinical trials in patients with hormone-receptor-positive tumors. However, high post-treatment Ki67 levels identify a group of patients at high risk for relapse, for which additional post-surgical treatment options should be developed. This is, to the best of our knowledge, the largest cohort on Ki67 measurements after neoadjuvant chemotherapy. As we had information on pre-and posttreatment-Ki67 levels available in 757 patients, our analysis had also sufficient statistical power to compare the prognostic impact of pre-and post-treatment Ki67 levels. It appeared that the measurement after neoadjuvant chemotherapy was more important than Ki67 level changes due to treatment. Our findings suggest that tumors with high Ki67 levels at surgery are at high relapse risk for the first three years after diagnosis. This could be explained by these patients had either already high Ki67 levels right at initial diagnosis and were insensitive to treatment or could have predominantly low proliferating, sensitive populations with some high proliferating, resistant subpopulations, which might have persisted until surgery and were dominant for the prognosis of the patient. Patients with low post-treatment Ki67 levels irrespective of their pre-treatment Ki67 level showed a relapse risk over the first 3 years comparable to those patients with a pCR; however the annual relapse risk maintained constant throughout the whole observation period.
Only few studies reported so far on the prognostic impact of Ki67 measurement after neoadjuvant chemotherapy. The largest, retrospectively collected cohort examined 284 surgical samples and 103 pairs from patients treated at the Royal Marsden Hospital 20 suggesting that Ki67 measured at surgery is a strong predictor of outcome for patients not achieving a pCR. No subgroup analysis by hormone-receptor-status was reported. Two recent retrospective cohorts with 102 and 64 patients examined Ki67 level before and after chemotherapy.
17
, 19 Whereas in the larger study only post-treatment Ki67 levels correlated with survival, the smaller found pre-and post-treatment Ki67 levels and estrogen-receptorstatus to be correlated with survival. Another report on a cohort of 100 patients has not found any significant changes in Ki67 levels from before to after neoadjuvant chemotherapy. 29 Proliferation and estrogen-receptor content are also measured by commercially available gene arrays; however, these tests have only been investigated on pretreatment core biopsies, but not after chemotherapy. 30 Pre-treatment Ki67 was measured in two neoadjuvant endocrine studies and an index (preoperative endocrine prognostic index, PEPI) including pathological tumor size, node status, Ki67 level, and ER status was developed in one trial and validated in the other. 31 Patients with a low PEPI score showed a very favorable outcome, not requiring chemothearpy. The PEPI score was similar after treatment with three different aromatase inhibitors in the ACOSOG Z1031 trial. 32 However, as these agents show comparable longterm outcome effects we do not know in how far this score is able to discriminate at shortterm a differential long-term efficacy of endocrine agents.
Explanations why response-guided chemotherapy did not result in different post-treatment Ki67 levels might be technical reasons: First, sample size of our analysis might have been too
Research. 16,33 However, use of three Ki67 levels should protect from incidental effects observed only with one or the other distinct cut-off. This approach is supported by the observation that mean Ki67 levels were identical between the treatment cohorts.
Central assessment of Ki67 can be considered as a criterion of quality of this work. However, due to high inter-observer variability, 34, 35 it can be questioned in how far these results can be used in clinical routine. Recent advances of automated image analysis might allow sufficient interlaboratory standardization 36 and might solve this disadvantage of Ki67.
In conclusion, Ki67 levels after neoadjuvant chemotherapy provide relevant independent and additional prognostic information in case of no pCR after neoadjuvant chemotherapy 
